KU-55933 (ATM Kinase Inhibitor)

For research use only. Not for use in humans.

目录号：S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

CAS No. 587871-26-9

KU-55933 (ATM Kinase Inhibitor)是一种有效的，特异性ATM抑制剂，在无细胞试验中IC50/K_i为12.9 nM/2.2 nM，与DNA-PK， PI3K/PI4K， ATR和mTOR相比，对ATM具有高度选择性。KU‑55933 (ATM Kinase Inhibitor)可抑制 autophagy‑initiating kinase ULK1 的激活从而导致自噬的显著减少。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 917.23	现货
5mg	RMB 571.66	现货
10mg	RMB 975.88	现货
50mg	RMB 3032.31	现货
200mg	RMB 7755.93	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的KU-55933 (ATM Kinase Inhibitor)发表文献237篇：

Cancer Cell, 2021, S1535-6108(20)30658-9

PubMed: 33450196 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nature, 2018, 560(7716):112-116

PubMed: 30022158 ( click the link to review the publication )

Cancer Cell, 2017, 32(3):342-359

PubMed: 28898696 ( click the link to review the publication )

Science, 2016, 352(6283):353-8

PubMed: 27013428 ( click the link to review the publication )

Nature, 2015, 528(7582):422-6

PubMed: 26649820 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14328

PubMed: 25799992 ( click the link to review the publication )

Cell, 2013, 155(5):1088-103

PubMed: 24267891 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1048-63

PubMed: 22915751 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(20)30951-5

PubMed: 33453166 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkaa1290

PubMed: 33469661 ( click the link to review the publication )

J Cell Biol, 2021, 220(2)e201807163

PubMed: 33404608 ( click the link to review the publication )

Cell Rep, 2021, 34(7):108713

PubMed: 33596428 ( click the link to review the publication )

Cell Rep, 2021, 34(9):108808

PubMed: 33657372 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:649328

PubMed: 33937245 ( click the link to review the publication )

Carcinogenesis, 2021, bgab002

PubMed: 33417668 ( click the link to review the publication )

Cancer Invest, 2021, 1-12

PubMed: 33683975 ( click the link to review the publication )

FEBS Open Bio, 2021, 10.1002/2211-5463.13152

PubMed: 33742560 ( click the link to review the publication )

Cell Death Differ, 2021, 10.1038/s41418-020-00733-4

PubMed: 33531658 ( click the link to review the publication )

Commun Biol, 2021, 4(1):484

PubMed: 33875784 ( click the link to review the publication )

EMBO J, 2021, e106336

PubMed: 33595114 ( click the link to review the publication )

Research Square, 2021, 10.21203/rs.3.rs-162979/v1

PubMed: N/A ( click the link to review the publication )

Cell Rep, 2021, 34(7):108744

PubMed: 33596421 ( click the link to review the publication )
Adv Sci (Weinh), 2020, 7(20):2000157

PubMed: 33101843 ( click the link to review the publication )

Mol Cell, 2020, S1097-2765(20)30723-1

PubMed: 33152268 ( click the link to review the publication )

Mol Cell, 2020, 22 pii: S1097-2765(20)30231-8

PubMed: 32353258 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6178

PubMed: 33268790 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5775

PubMed: 33188175 ( click the link to review the publication )

Nat Commun, 2020, 26;11(1):2641

PubMed: 32457376 ( click the link to review the publication )

Nat Commun, 2020, 8;11(1):2876

PubMed: 32513994 ( click the link to review the publication )

Nucleic Acids Res, 2020, 6;48(6):2982-3000

PubMed: 31970415 ( click the link to review the publication )

Cell-Rep, 2020, 18;30-7-:2402-2415-e5

PubMed: 32075772 ( click the link to review the publication )

Cell Rep, 2020, 18;30(7):2083-2093 e5

PubMed: 32075732 ( click the link to review the publication )

Cell Rep, 2020, 14;31(2):107518

PubMed: 32294440 ( click the link to review the publication )

Cell Rep, 2020, 32(9):108080

PubMed: 32877684 ( click the link to review the publication )

Cell Rep, 2020, 31(10):107745

PubMed: 32521270 ( click the link to review the publication )

Elife, 2020, 30;9:e51466

PubMed: 32223892 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 77(4):735-749

PubMed: 31297568 ( click the link to review the publication )

mBio, 2020, 11(1)

PubMed: 32071277 ( click the link to review the publication )

mBio, 2020, 11(3):e01190-20

PubMed: 32546626 ( click the link to review the publication )

Cancers (Basel), 2020, 28;12(6):E1388

PubMed: 32481544 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2467

PubMed: 32878283 ( click the link to review the publication )

PLoS Pathog, 2020, 16(6):e1008514

PubMed: 32479542 ( click the link to review the publication )

Arterioscler Thromb Vasc Biol, 2020, ATVBAHA120315206

PubMed: 33356386 ( click the link to review the publication )

Arch Toxicol, 2020, 10.1007/s00204-020-02712-7

PubMed: 32189037 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Aging (Albany NY), 2020, 22;12(6):4688-4710

PubMed: 32201398 ( click the link to review the publication )
DNA Repair (Amst), 2020, 87:102803

PubMed: 31991288 ( click the link to review the publication )

Sci Rep, 2020, 10(1):14455

PubMed: 32879366 ( click the link to review the publication )

Front Pharmacol, 2020, 11:601468

PubMed: 33628174 ( click the link to review the publication )

Cell Mol Biol Lett, 2020,

PubMed: 32874188 ( click the link to review the publication )

PLoS One, 2020, 15(1):e0223463

PubMed: 31914134 ( click the link to review the publication )

Int J Radiat Biol, 2020, 96(4):461-468

PubMed: 31859574 ( click the link to review the publication )

Sci Rep, 2020, 10(1):2200

PubMed: 32042076 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):1490

PubMed: 32517381 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9):E2356

PubMed: 32825402 ( click the link to review the publication )

Nat Chem Biol, 2020, 10.1038/s41589-020-0600-3

PubMed: 32719556 ( click the link to review the publication )

J Biol Chem, 2020, 295(1):125-137

PubMed: 31753920 ( click the link to review the publication )

Nat Commun, 2020, 11(1):123

PubMed: 31913317 ( click the link to review the publication )

Med Mol Morphol, 2020, 10.1007/s00795-020-00264-4

PubMed: 32816116 ( click the link to review the publication )

Mol Cell, 2019, 75(6):1299-1314

PubMed: 31353207 ( click the link to review the publication )

Mol Cell, 2019, 74(4):651-663.e8

PubMed: 30954402 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2910

PubMed: 31266951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1577

PubMed: 30952868 ( click the link to review the publication )

Nat Commun, 2019, 10(1):87

PubMed: 30622252 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz518

PubMed: 31184714 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-3388

PubMed: 31515237 ( click the link to review the publication )

J Cell Biol, 2019, 218(7):2113-2123

PubMed: 31123184 ( click the link to review the publication )

Cell Rep, 2019, 26(8):2194-2211.e6

PubMed: 30784599 ( click the link to review the publication )

Cell Rep, 2019, 28(3):735-745

PubMed: 31315051 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0393-7

PubMed: 31320750 ( click the link to review the publication )
Cancers (Basel), 2019, 11(12)

PubMed: 31766690 ( click the link to review the publication )

Cancer Discov, 2019, 9(9):1306-1323

PubMed: 31217297 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Neoplasia, 2019, 21(12):1143-1150

PubMed: 31759252 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:8535163

PubMed: 31641425 ( click the link to review the publication )

J Cell Physiol, 2019, 234(11):21294-21306

PubMed: 31054162 ( click the link to review the publication )

J Virol, 2019, 93(14)

PubMed: 31043526 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13097

PubMed: 31511540 ( click the link to review the publication )

J Biol Chem, 2019, 294(17):7037-7045

PubMed: 30858175 ( click the link to review the publication )

J Biol Chem, 2019, 294(8):2827-2838

PubMed: 30598506 ( click the link to review the publication )

Retrovirology, 2019, 16(1):13

PubMed: 31036006 ( click the link to review the publication )

Sci Adv, 2019, 5(3):eaav1118

PubMed: 30944854 ( click the link to review the publication )

Sci Adv, 2019, 5(5):eaav3235

PubMed: 31086816 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.215210

PubMed: 31727767 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(10):5243-5259

PubMed: 30976812 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(21):10977-10993

PubMed: 31612207 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2019, 105(4):861-874

PubMed: 31419512 ( click the link to review the publication )

J Exp Med, 2019, 216(7):1648-1663

PubMed: 31097467 ( click the link to review the publication )

J Pineal Res, 2019, 67(4):e12603

PubMed: 31370106 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(4):413-421

PubMed: 29531308 ( click the link to review the publication )

Cell Res, 2018, 28(7):756-770

PubMed: 29844578 ( click the link to review the publication )

Mol Cell, 2018, 71(2):332-342

PubMed: 30017584 ( click the link to review the publication )

Mol Cell, 2018, 69(5):879-892.e5

PubMed: 29478807 ( click the link to review the publication )
Nat Struct Mol Biol, 2018, 25(3):261-269

PubMed: 29483652 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5351

PubMed: 30559436 ( click the link to review the publication )

Nat Commun, 2018, 9(1):697

PubMed: 29449575 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1317

PubMed: 29615613 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10119-10131

PubMed: 30165463 ( click the link to review the publication )

Sci Adv, 2018, 4(12):eaat5077

PubMed: 30585287 ( click the link to review the publication )

Cancer Res, 2018, 78(18):5363-5374

PubMed: 30054334 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3393-3403.e5

PubMed: 30257201 ( click the link to review the publication )

Int J Cancer, 2018,

PubMed: 29363109 ( click the link to review the publication )

Redox Biol, 2018, 14:645-655

PubMed: 29172151 ( click the link to review the publication )

Cancer Lett, 2018, 419:280-290

PubMed: 29378238 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):164

PubMed: 29415984 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):660

PubMed: 29855474 ( click the link to review the publication )

FASEB J, 2018, 32(4):1818-1829

PubMed: 29162700 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(23):4024-4035

PubMed: 30107443 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 39(10):1645-1660

PubMed: 29849127 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 39(12):1874-1884

PubMed: 29921885 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):709-720

PubMed: 29328365 ( click the link to review the publication )

Virology, 2018, 523:121-128

PubMed: 30119013 ( click the link to review the publication )

Arch Biochem Biophys, 2018, 644:93-99

PubMed: 29352966 ( click the link to review the publication )

Transl Oncol, 2018, 11(4):988-998

PubMed: 29940414 ( click the link to review the publication )

Oncol Rep, 2018, 39(5):2071-2080

PubMed: 29565449 ( click the link to review the publication )
Oncol Rep, 2018, 40(4):2363-2370

PubMed: 30066882 ( click the link to review the publication )

Radiat Res, 2018, 189(5):505-518

PubMed: 29474155 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):6608-6614

PubMed: 30405800 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(9):1697-1711

PubMed: 30323964 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(16):8311-8325

PubMed: 30010936 ( click the link to review the publication )

Blood, 2017, 129(21):2882-2895

PubMed: 28283481 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2039

PubMed: 29229926 ( click the link to review the publication )

EMBO J, 2017, 2;36(9):1261-1278

PubMed: 28320736 ( click the link to review the publication )

Genes Dev, 2017, 31(7):648-659

PubMed: 28446595 ( click the link to review the publication )

Genes Dev, 2017, 31(3):318-332

PubMed: 28242626 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4567-4578

PubMed: 28698210 ( click the link to review the publication )

J Cell Biol, 2017, 216(3):623-639

PubMed: 28228534 ( click the link to review the publication )

EMBO Rep, 2017, 18(5):781-796

PubMed: 28325772 ( click the link to review the publication )

Cancer Lett, 2017, 390:48-57

PubMed: 28093285 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):133

PubMed: 28950914 ( click the link to review the publication )

Free Radic Biol Med, 2017, 108:750-759

PubMed: 28431961 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3019

PubMed: 28837154 ( click the link to review the publication )

Cell Death Dis, 2017,

PubMed: 28518141 ( click the link to review the publication )

Stem Cells Transl Med, 2017, 6(6):1504-1514

PubMed: 28544661 ( click the link to review the publication )

Sci Total Environ, 2017, 1599:375-390

PubMed: 28477133 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16115

PubMed: 29170437 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12424-12435

PubMed: 28592488 ( click the link to review the publication )

Int J Oncol, 2017, 50(1):290-296

PubMed: 27959407 ( click the link to review the publication )

Eur J Pharm Sci, 2017, 109:223-232

PubMed: 28822757 ( click the link to review the publication )
Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

Virology, 2017, 510:9-21

PubMed: 28689087 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):338

PubMed: 28521819 ( click the link to review the publication )

Oncol Rep, 2017, 38(1):591-597

PubMed: 28560404 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181530

PubMed: 28746371 ( click the link to review the publication )

Nutr Cancer, 2017, 69(8):1281-1289

PubMed: 29111814 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(18):10564-10582

PubMed: 28985345 ( click the link to review the publication )

Genome Biol, 2017, 18(1):224

PubMed: 29178945 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1357-1366

PubMed: 27820601 ( click the link to review the publication )

Mol Cell, 2016, 61(3):405-418

PubMed: 26774285 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(10):4745-62

PubMed: 26939887 ( click the link to review the publication )

Genes Dev, 2016, 30(3):321-36

PubMed: 26833731 ( click the link to review the publication )

J Cell Biol, 2016, 212(4):399-408

PubMed: 26880199 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.15129

PubMed: 27269284 ( click the link to review the publication )

Oncogene, 2016, 35(5):567-76

PubMed: 25893301 ( click the link to review the publication )

Cell Death Discov, 2016, 2:16011

PubMed: 27551505 ( click the link to review the publication )

Cell Death Discovery, 2016, 10.1038/cddiscovery.2016.11

PubMed: ( click the link to review the publication )

FASEB J, 2016, 30(8):2899-914

PubMed: 27142525 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:4313204

PubMed: 28042385 ( click the link to review the publication )

Cell Discov, 2016, 2:16016

PubMed: 27462463 ( click the link to review the publication )

J Immunol, 2016, 197(7):2918-29

PubMed: 27559048 ( click the link to review the publication )

J Cell Sci, 2016, 129(16):3167-77

PubMed: 27383768 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 292:65-74

PubMed: 26708502 ( click the link to review the publication )

Chem Res Toxicol, 2016, 29(1):26-39

PubMed: 26630137 ( click the link to review the publication )
Cell Cycle, 2016, 15(1):84-94

PubMed: 26771713 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):725

PubMed: 27613518 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2016, 77(1):169-80

PubMed: 26590990 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0167454

PubMed: 27907109 ( click the link to review the publication )

Oncotarget, 2016, 7(38):60807-60822

PubMed: 27602502 ( click the link to review the publication )

Sci Rep, 2016, 6:27379

PubMed: 27271479 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29359-70

PubMed: 27121065 ( click the link to review the publication )

Oncotarget, 2016, 7(31):49800-49818

PubMed: 27391441 ( click the link to review the publication )

Mutat Res Genet Toxicol Environ Mutagen, 2016, 795:1-6

PubMed: 26774662 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(8):1004-13

PubMed: 26214134 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(11):1446-57

PubMed: 26502055 ( click the link to review the publication )

Leukemia, 2015, 29(5):1133-42

PubMed: 25371178 ( click the link to review the publication )

Genes Dev, 2015, 29(11):1151-63

PubMed: 26019174 ( click the link to review the publication )

Nanoscale, 2015, 7(47):20211-9

PubMed: 26575637 ( click the link to review the publication )

Oncogene, 2015, 34(23):2978-90

PubMed: 25132270 ( click the link to review the publication )

Arch Toxicol, 2015, 89(11):2015-25

PubMed: 25294323 ( click the link to review the publication )

PLoS Genet, 2015, 11(10):e1005563

PubMed: 26430909 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(5):1649-64

PubMed: 26175935 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Mol Biol Cell, 2015, 26(12):2217-26

PubMed: 25904336 ( click the link to review the publication )

Sci Rep, 2015, 5:11465

PubMed: 26095524 ( click the link to review the publication )

J Biol Chem, 2015, 290(46):27545-56

PubMed: 26420486 ( click the link to review the publication )

Cell Signal, 2015, 27(5):951-60

PubMed: 25683911 ( click the link to review the publication )
Cancer Biol Ther, 2015, 16(11):1585-92

PubMed: 26382920 ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(20):3248-60

PubMed: 26312527 ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0142561

PubMed: 26556501 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0145994

PubMed: 26717578 ( click the link to review the publication )

Int J Radiat Biol, 2015, 10.3109/09553002.2015.1029595

PubMed: 25912236 ( click the link to review the publication )

Cell Biol Int, 2015, 10.1002/cbin.10439

PubMed: 25598069 ( click the link to review the publication )

Anticancer Res, 2015, 35(7):3829-38

PubMed: 26124328 ( click the link to review the publication )

Nat Neurosci, 2014, 17(6):813-21

PubMed: 24793032 ( click the link to review the publication )

Cell Death Differ, 2014, 10.1038/cdd.2014.159

PubMed: 25301067 ( click the link to review the publication )

Mol Cancer, 2014, 13:36

PubMed: 24568192 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.268

PubMed: 25132265 ( click the link to review the publication )

Cancer Discov, 2014, 4(10):1198-213

PubMed: 25100205 ( click the link to review the publication )

DNA Repair , 2014, 21:140-7

PubMed: 24795278 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(5):934-44

PubMed: 24480460 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1842(7):1071-9

PubMed: 24726882 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1842(7):1088-96

PubMed: 24726884 ( click the link to review the publication )

J Biol Chem, 2014, 289(23):16072-84

PubMed: 24782314 ( click the link to review the publication )

Toxicol Appl Pharm, 2014, 282(2):227-236

PubMed: 25450480 ( click the link to review the publication )

Cell Cycle, 2014, 13(11):1777-87

PubMed: 24732096 ( click the link to review the publication )

Neurotox Res, 2014, 25(2):193-207

PubMed: 23996700 ( click the link to review the publication )

Radiat Res, 2014, 181(6):650-8

PubMed: 24785587 ( click the link to review the publication )

Theriogenology, 2014, 12(5):e1001856

PubMed: 24800743 ( click the link to review the publication )
Proteomes, 2014, 2, 451-467

PubMed: ( click the link to review the publication )

Julius Maximilians Universit, 2014, Kumari G

PubMed: ( click the link to review the publication )

Proteomes, 2014, 2(3):451-467

PubMed: 28250390 ( click the link to review the publication )

PLoS One, 2014, 9(6):e98891

PubMed: 24902048 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10157-69

PubMed: 24021630 ( click the link to review the publication )

Sci Signal, 2013, 6(259):ra5

PubMed: 23354688 ( click the link to review the publication )

Neurotox Res, 2013, 25(2):193-207

PubMed: 23996700 ( click the link to review the publication )

FEBS Lett, 2013, 587(21):3437-43

PubMed: 24021642 ( click the link to review the publication )

PLoS One, 2013, 9(1):e84899

PubMed: 24454762 ( click the link to review the publication )

PLoS One, 2013, 8(11):e80313

PubMed: 24282534 ( click the link to review the publication )

J Gen Virol, 2013, 94(Pt 12):2664-2669

PubMed: 24045107 ( click the link to review the publication )

Cell Cycle, 2013, 12(7):1105-18

PubMed: 23462183 ( click the link to review the publication )

Autophagy, 2012, 8(2):236-51

PubMed: 22240589 ( click the link to review the publication )

J Immunol, 2012, 188(5):2266-75

PubMed: 22287717 ( click the link to review the publication )

J Biol Chem, 2012, 287(26):22112-22

PubMed: 22566699 ( click the link to review the publication )

J Biol Chem, 2012, 287(12):8803-15

PubMed: 22270370 ( click the link to review the publication )

Food Chem Toxicol, 2012, 55:214-21

PubMed: 23274058 ( click the link to review the publication )

Int J Radiat Biol, 2012, 88(7):507-14

PubMed: 22449004 ( click the link to review the publication )

J Virol, 2011, 85(23):12547-56

PubMed: 21917957 ( click the link to review the publication )

J Biol Chem, 2011, 286(10):8394-404

PubMed: 21148313 ( click the link to review the publication )

Mech Ageing Dev, 2011, 132(11-12):543-51

PubMed: 21945951 ( click the link to review the publication )

产品安全说明书

ATM/ATR抑制剂选择性比较

生物活性

产品描述

靶点

ATM ^[1]
(Cell-free assay)

12.9 nM

体外研究

KU-55933是有效的特定ATM抑制剂，IC50为13 nM，K_i值为2.2 nM。KU-55933也抑制DNA-PK和PI3K，IC50分别为2.5和16.6 μM。KU-55933也抑制mTOR活性，IC50为9.3 μM。KU-55933有效作用于ATM依赖的磷酸化作用。KU-55933抑制ATM依赖的磷酸化作用，存在剂量依赖性，IC50为300 nM。小于30 μM时，KU-58050不能抑制p53的ATM-依赖性磷酸化作用（位点为第15位丝氨酸）。在UV-诱导的H2AX（位点为第139位丝氨酸）, NBS1（位点为第343为丝氨酸）, CHK1（位点为第345位丝氨酸）,及SMC1（位点为第966位丝氨酸）中，加入KU-55933没有明显作用效果。紫外处理时，KU-55933切除由电离辐射诱导的ATM磷酸化底物。KU-55933使HeLa细胞对电离辐射敏感。在癌细胞中，KU-55933抑制生长因子诱导的Akt的磷酸化作用。KU-55933抑制癌细胞增殖。KU-55933抑制ATM，通过阻断下游TAp63α的激活，提高存活力。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
DU-145	NXHx[oxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1mzc2lEPTB;Mz6yO\|M2OiEQvF2=	NE\6XHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HuO-3N1	NEO0cm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTRwMUexOFIh\|ryP	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
LAMA-84	NVjrOZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTRwNUi0OlUh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
CAL-72	M{HFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\NeJY4UUN3ME21MlQ5ODh2IN88US=>	NUP0c4RuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
LoVo	Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTZwOUOyN\|kh\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
HH	M3rrb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnz1TWM2OD16LkK3OlcyKM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
SK-MEL-3	NXHZdmFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRThwMki1O\|Uh\|ryP	M1LIOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
KM12	NGjzPIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPrVXl3UUN3ME25MlIyOTR{IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
NCI-H1437	NYnpZoRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUX5cWdpUUN3ME25MlgxQTdizszN	M1KyRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
NCI-H1838	NGToSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXBO2tbUUN3ME2xNU4yQDZ3IN88US=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
J-RT3-T3-5	NEPPdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moj3TWM2OD1zMT6yOFE4KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
GOTO	MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTFzLk[5PVYh\|ryP	M4XTS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
LB2241-RCC	NYX4RlFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGr6N3VKSzVyPUGxMlcyQDZizszN	NEPDWZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
ES7	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;2TWM2OD1zMT63PFgh\|ryP	MonHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
KP-N-YS	NGfqVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zHOGlEPTB;MUKuOlM2PCEQvF2=	M4np[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
CAL-12T	NWj4dGZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jyPGlEPTB;MUOuOlE4KM7:TR?=	NUPKfWtNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
COLO-684	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17kZ2lEPTB;MUSuNVU3QSEQvF2=	MmfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
DOK	Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HtT2lEPTB;MUWuN\|MzQSEQvF2=	NVrlPIR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
Hs-578-T	NUDCVFZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHH1eVRKSzVyPUG1MlQyQDJizszN	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
D-423MG	NYXlSJZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDBTWM2OD1zNT61NlM3KM7:TR?=	NVnRbmdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
DBTRG-05MG	M{W3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPhS\|lKSzVyPUG1MlYyOTFizszN	MnPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
VM-CUB-1	NUTvbHpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2W0bGlEPTB;MUWuPVg1QSEQvF2=	NYLJ[G9bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
KG-1	NVqyfopuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3nTWM2OD1zNj6wPVk3KM7:TR?=	NGfzU5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
8305C	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTF4LkG4PFkh\|ryP	NVnPeZV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
HuH-7	M1vhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrIe3NKSzVyPUG2MlI3PzRizszN	NYPWXIQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
LXF-289	M3;lR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnTUY5lUUN3ME2xOk4zPzR5IN88US=>	MnvwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
NCI-H1793	M3;hbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTF4LkS3NVIh\|ryP	MoW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
ChaGo-K-1	NH[yT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEKyTo1KSzVyPUG2MlY2PjhizszN	NIHX[I49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
GCIY	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTF4Lke5NFUh\|ryP	NWrIboVRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
SK-MEL-28	NFfnWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFi4S\|FKSzVyPUG3MlA1PzVizszN	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
NCI-SNU-1	NWG2XIRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mke5TWM2OD1zNz6xNlY6KM7:TR?=	NXX3b3Y6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
CTB-1	M3;SdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzuXnY1UUN3ME2xO{4zOjV7IN88US=>	NWjwXGZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
NCI-H82	NX\oR5RMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTF5LkS1O\|Mh\|ryP	NHzsTpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HCC2998	MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTF5Lk[3N\|Mh\|ryP	M2nIR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
NCI-H2030	MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTF6LkG5PVch\|ryP	NFH1c\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HuP-T3	M1PFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTF6LkW4PFgh\|ryP	MmDEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
697	M4n0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDab5hqUUN3ME2xPU4xOjBzIN88US=>	NGjSbHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
MLMA	MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTTTWM2OD1zOT6wOVU4KM7:TR?=	NEHlc3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HCC70	NIPnT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;ndIJKSzVyPUG5MlQ5QSEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
A704	NFj0T5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHGTWM2OD1zOT64N\|A2KM7:TR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
D-283MED	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfNTWM2OD1{MD61N\|M6KM7:TR?=	M1vtNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
U031	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTjdpFbUUN3ME2yNU4yPDh7IN88US=>	MoewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
HSC-3	NI\qVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\NTWM2OD1{MT6xPFM2KM7:TR?=	NVnrNZZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
JVM-3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTJ{LkWwOkDPxE1?	MkDZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
Mewo	M2HUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M133cmlEPTB;MkKuOVA4OyEQvF2=	NVXISG06RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
YH-13	NUXGfIdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjkUJFJUUN3ME2yNk42OTJ\|IN88US=>	Ml\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzMeGVKSzVyPUKyMlU5PzlizszN	M3zZVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
HCC2157	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4qzdmlEPTB;MkKuPFA2PCEQvF2=	MlPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
SNU-449	NWTZdlU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLlb3hKSzVyPUKyMlg4PDhizszN	NI\2R409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
Ramos-2G6-4C10	M4DZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HwcWlEPTB;MkKuPVYh\|ryP	NFuyUG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
CHL-1	M3;RUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTJ\|LkeyPVIh\|ryP	M2LaNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
SK-MEL-30	M3LKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XJeWlEPTB;MkSuOFY3OiEQvF2=	NVW5SWdTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
PANC-08-13	MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoP4TWM2OD1{NT6wPVM5KM7:TR?=	NVLJcVJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
QIMR-WIL	M1\2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTJ3LkG4OVgh\|ryP	NX3BNnRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
BFTC-905	MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvyPGJiUUN3ME2yOU42QTR2IN88US=>	NGn5TJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
GI-1	NWTKWphqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\jcotKSzVyPUK1MlcxPTVizszN	NUSx[VRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
MDA-MB-415	NUm4UFdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWCzZlBlUUN3ME2yOk42ODN\|IN88US=>	MlG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
GT3TKB	MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTJ4LkWzOFIh\|ryP	M3TZVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
DEL	M4jtbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzIdW9KSzVyPUK2Mlg{PTZizszN	M4TmTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
KOSC-2	NX\GdY4zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHjTWM2OD1{Nj65NFc2KM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
RVH-421	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\XPWlEPTB;MkeuNlkzOSEQvF2=	M1ywWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
EW-13	NXTlblhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYmzfJVmUUN3ME2yO{41OzB6IN88US=>	NWe5[nlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
639-V	NFzteHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrPVW5KSzVyPUK3MlUyOTlizszN	NUjkTJBTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
A2780	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;CTWM2OD1{Nz62OFEh\|ryP	NInhfZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
SW982	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTJ5LkmwOVIh\|ryP	M3zndVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
SW1710	M1T4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NImweGZKSzVyPUK4MlA6QDFizszN	NWPlXWRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
HCC1569	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\idlJKSzVyPUK4MlQ5QTdizszN	NGnqUJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
MV-4-11	NWHifWlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHH5RYtKSzVyPUK4MlU4OzVizszN	NHLRUZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
BHT-101	MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTJ6Lk[1O\|Ih\|ryP	NEfNcHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
Ca9-22	NYrCNm5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPOcGNKSzVyPUK4MlcyPCEQvF2=	NH[4N2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HAL-01	NYO5T2M6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXztPG9YUUN3ME2yPE44PjF3IN88US=>	MkG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
D-263MG	NHPScJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXe2Zo12UUN3ME2yPU4{PDRizszN	NGrNflE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
NEC8	NIjiPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTuTWM2OD1{OT61OVQ5KM7:TR?=	NH\GSJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
EKVX	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPQZVJKSzVyPUOxMlU5PDdizszN	NY\hdmU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
EM-2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTNzLk[zNFQh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
MFM-223	NFXlbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3jOHFEUUN3ME2zNU45ODl6IN88US=>	NYryR4NuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
SK-PN-DW	NU[3R3A3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NID5TXFKSzVyPUOyMlE1ODZizszN	NG[wWpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HuO9	NUfQXFRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTN{LkWyPFIh\|ryP	NEntVmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
MHH-PREB-1	M1n5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnGV2xzUUN3ME2zNk43OjN2IN88US=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
OVCAR-4	MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTN{LkizOlMh\|ryP	MluyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
NCI-H1648	NGLjZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFruZnpKSzVyPUOyMlg3PTFizszN	Moi1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
MKN1	NYG3dXN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljFTWM2OD1\|ND6xNVAyKM7:TR?=	M3vNNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
KYSE-450	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTOWHFKSzVyPUO0MlY1PDRizszN	MnHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
ES8	NXjYdollT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPSTWM2OD1\|ND64PVc2KM7:TR?=	MmjuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
MS-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHoVZhoUUN3ME2zOE46PTV2IN88US=>	NHTh[G49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HOP-92	NXfyeVN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrMTWM2OD1\|NT65Nlc4KM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
SKG-IIIa	NWPvVFRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;zTGlEPTB;M{[uNlU3OSEQvF2=	M1HoRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
TE-11	Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTN4LkWyOFMh\|ryP	M4fvN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
SK-NEP-1	M3\TZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVr3W2QzUUN3ME2zO{43PzR2IN88US=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
DB	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1v0fGlEPTB;M{euPVE5PSEQvF2=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
IA-LM	NHOyR5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTN6LkCyN\|kh\|ryP	NHfKVFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
COLO-829	NF[1U4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XIbWlEPTB;M{iuOFE2QSEQvF2=	MnfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
TGBC11TKB	NYHLTIZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTN7LkG0NFgh\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
CAL-51	NVLpdop6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrMZ5FvUUN3ME20NE4xPjF{IN88US=>	MkTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
NCI-H2228	M{nhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3p[FdGUUN3ME20NE4{PjZ{IN88US=>	NWLycG17RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
C32	MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\TNnB4UUN3ME20NE41ODJ2IN88US=>	NV:ycVRkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
KU-19-19	NGLYXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTRyLke2PFMh\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
KNS-62	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\BRWlEPTB;NECuPFM5OSEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
FADU	NWjZXplqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTRzLkK1NFIh\|ryP	NEDXeWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
CAL-33	MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7GTY5KUUN3ME20Nk43PzR7IN88US=>	M1PTcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
CHP-134	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTR{Lki0PVYh\|ryP	MkTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
HDLM-2	MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljiTWM2OD12Mj65NFg1KM7:TR?=	NXnzbZlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
NBsusSR	NHnnRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTR\|LkC3NlUh\|ryP	MkHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
SW954	MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLjUGZwUUN3ME20N{4yODV\|IN88US=>	NFzzTG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HCC1806	M16wVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYntPHlQUUN3ME20N{41OTFizszN	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
VMRC-RCZ	M2PNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDKTWM2OD12Mz60OVg3KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
A549	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTR\|LkmzNUDPxE1?	Mn\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
NKM-1	MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTR\|Lkm1OVgh\|ryP	NEDQOHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
DMS-273	Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;1XHRGUUN3ME20OE44PTZ5IN88US=>	NFvs[Vg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
TYK-nu	NFTPO\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfHdVVKSzVyPUS1MlEzOzRizszN	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
KALS-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\x[nBKSzVyPUS1MlE1PiEQvF2=	M4jGU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
A101D	M{fMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXNTWM2OD12NT60OFU3KM7:TR?=	NGrSSZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
G-361	NFu4NWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1G3NmlEPTB;NE[uNlE{QCEQvF2=	M3fLe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
KARPAS-299	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlq5TWM2OD12Nj6zOVE3KM7:TR?=	MmrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
RS4-11	NYPlfnJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILMcGRKSzVyPUS2MlU1OiEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
HT-1376	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYmyTopMUUN3ME20Ok44PDJ4IN88US=>	M3rQOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
SK-N-AS	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LnWmlEPTB;NE[uO\|gzOiEQvF2=	NIHCcoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
MG-63	NWLTcmpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTR4LkmwN\|Yh\|ryP	NVPWdXFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
EPLC-272H	M2PhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jCVGlEPTB;NE[uPVUxOyEQvF2=	M1vwXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
BALL-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDqTWM2OD12Nz64N\|Ih\|ryP	NGTOR4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
LCLC-97TM1	M3PyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTR6LkKwNkDPxE1?	NVLTZYZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
HO-1-N-1	MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHuVIptUUN3ME20PE46Pjd4IN88US=>	MlTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
MFE-280	NFj2O\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\JfWhKSzVyPUS5MlQ3OTdizszN	MoPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
NCI-H526	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTR7LkixOlMh\|ryP	NYfveJl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
D-566MG	NY\5Uo1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{OwNmlEPTB;NEmuPVA6PiEQvF2=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
BB30-HNC	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnnd44yUUN3ME20PU46PDl6IN88US=>	NYLuN4VmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
SK-N-DZ	NVW5ZmZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzGfWlUUUN3ME21NE4xPDhzIN88US=>	NGDZSXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HepG2	M1T5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWOxNOKh\|ryP	MV2yOEBp		NYjiWWV{[myxY3vzJHNENUmLSUOtbY5lfWOnZDDTJJBp[XOnIHHydoV{fA>?	NYfS[oU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlcyOjNpPkK1OVI4OTJ\|PD;hQi=>
HepG2	MV\GeY5kfGmxbjDBd5NigQ>?	NH7F[2YyOMLizszN	NY\VUZdYOjRiaB?=		M3;rVpN2eHC{ZYPz[ZMhfGinIIDoc5NxcG:{eXzheIlwdnNib3[gRXROKG:wIGPldlE6QDFuIFPob\|Ehd25iU3XyN\|Q2NCCFaHuyJI9vKFSqck[4MEBidmRiQ3TrNkBwdiCWeYKxOUBqdmS3Y3XkJIJ6KFOFLVnJTVM>	NISwOnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyO\|EzOyd-MkW1NlcyOjN:L3G+
KATO III	NW\TSHJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPNe4czNjVxNT:3MlUh\|ryP		NF;1T4VFVVOR	MV3lcohidmOnczD0bIUhfG:6aXPpeJkhd2Zib3zhdIFzcWJ?	NVTiXFFURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OFE4OThpPkK0PFQyPzF6PD;hQi=>
hTCEpi	M36zT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX:2SFBLOTBizszN		NVPaTlRzTE2VTx?=	MUTwdoV3\W62czD0bIUh[3m2b4DheIhq[yCnZn\lZ5Qhd2ZiSGPWMVE>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN5MEizOUc,OjR\|N{C4N\|U9N2F-
MCF10A	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\NSphlOTBizszN	M4DYdVI1KGh?	Moe1SG1UVw>?	M1TVcJBwfGWwdHnheIV{KHSqZTDjfZRwfG:6aXPpeJkhd2ZiR1G=	M1jF[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUWwOVk2Lz5{NEG1NFU6PTxxYU6=
HL-60	MUXGeY5kfGmxbjDBd5NigQ>?	NF\lU\|kyOCEQvF2=	NHjicXExNjViaB?=	MXrEUXNQ	NELqS45z\WS3Y3XzJJBpd3OyaH;yfYxifGmxbjDv[kBEcGt{wrC=	M4e2SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUO0OFEyLz5{M{mzOFQyOTxxYU6=
MCF-7	MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXmx[olKOS1zMEFOwG0>	MVOyOEBp	M2rFb2ZDWw>?	MXPpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v	M1rHOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUi1N\|Q4Lz5{M{G4OVM1PzxxYU6=
HeLa	NY\1Vm1NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUixMVExOM7:TR?=	MXWyOEBp	Mn;ESmJU	NFzSeXFqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w	NH\QVmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G4OVM1Pyd-MkOxPFU{PDd:L3G+
SH-SY5Y	MVXGeY5kfGmxbjDBd5NigQ>?	M1[1[lExyqEQvF5CpC=>	Mn\ENlQhcA>?		MXjpcohq[mm2czDjcIlweXWrbn;sMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJJA2Ow>?	M4L1UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkK3Nlk1Lz5{Mk[yO\|I6PDxxYU6=
IMR-32	NXnKcWpSTnWwY4Tpc44hSXO\|YYm=	NXzncm01OTEEoN88UeKh	MXmyOEBp		NH7MUnFqdmirYnn0d{BkdGmxcYXpco9tNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKHB3Mx?=	NV34NJdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NlczQTRpPkKyOlI4Ojl2PD;hQi=>
A549	NXvnWVdqTnWwY4Tpc44hSXO\|YYm=	MXOxNOKh\|ryPwrC=	MoP2NUBp		NVXHeXFVe3WycILld5NmeyCQYX7vMWNwNWmwZIXj[YQheDV\|IHHjZ5VufWyjdHnvci=>	MlXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NUmzNlEoRjJ{NUW5N\|IyRC:jPh?=
T47D	MlLUSpVv[3Srb36gRZN{[Xl?	NX:yNoNlOjEEoH3N	NH7peJQzPCCq	MVfEUXNQ	M2mxXZBz\X[nboTzJGlTNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gTe67Ss7z	M2rpbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUS0PFA2Lz5{MUG0OFgxPTxxYU6=
A29 MEF	MmiySpVv[3Srb36gRZN{[Xl?	NXvrV4g3OTEEoN88UeKh	NYXK[\|lWOWh?		NXuxXHZE[myxY3vzxsB1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHreEBifCCVZYK0O\|PDqA>?	NXXVTmJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwOVM4QDFpPkKwNFU{PzhzPD;hQi=>
MDA-MB-453	MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTQOU01OCEQvF2=	NF73fHY4OiCq		MWXJR\|UxKG:oIEGwJO69VQ>?	NGGycII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC1N\|c5OSd-MkCwOVM4QDF:L3G+
PC-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TrdlUuPDBizszN	MmDvO\|IhcA>?		MV;JR\|UxKG:oIEGwJO69VQ>?	NGq3b3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC1N\|c5OSd-MkCwOVM4QDF:L3G+
U2OS	NWDGZZJHTnWwY4Tpc44h[XO\|YYm=				MnL0TY5pcWKrdHnvckBw\iCDVF2gbY4hcHWvYX6gWVJQWyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJA2OyCyaH;zdIhwenmuYYTpc44h[XRiU3XyNVUhemW\|aXT1[UwhUUN3MDC9JFAvOjVizszNMi=>	NWr4UldyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2N\|I6PjVpPkK2OlMzQTZ3PD;hQi=>
MCF7	MVnGeY5kfGmxbjDhd5NigQ>?		NGC0O3AyKGi{		Mon1TY5pcWKrdHnvckBw\iCDVF2gb4lv[XOnIHnuJIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiMTDodkBjgSCrbX31co9ndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjNizszNMi=>	NFfNZWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[zNlk3PSd-Mk[2N\|I6PjV:L3G+
BJ	MUTGeY5kfGmxbjDhd5NigQ>?	NYnJO5FxOTBidV2=	NEexTYMyOCCmYYnz		MU\TeZBxemW\|c3nvckBw\iC\|ZX7ld4NmdmOnIHnuJIh2dWGwIFLKJINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGOnbHygcpVu[mW{IHH0JFExKHWPIHHmeIVzKDFyIHThfZMh[nlic3Xu[ZNk\W6lZTDy[ZZmenOjbDDhd5NigQ>?	M{XjSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{[3NFg2Lz5zNke2O\|A5PTxxYU6=
BJ	MmXHSpVv[3Srb36gZZN{[Xl?	NFXnfooyOCC3TR?=	M4f6eFExKGSjeYO=		NHzFc5NKdmirYnn0bY9vKG:oIHH0ZZhq[SC2ZXzhcodq\WO2YYPpZU1ufXSjdHXkJIlvKGi3bXHuJGJLKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHPlcIwhdnWvYnXyJIF1KDFyIIXNJIFnfGW{IEGwJIRigXNiYomgd4Vv\XOlZX7j[UBz\X[ncoPhcEBie3OjeR?=	M1z5bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{[3NFg2Lz5zNke2O\|A5PTxxYU6=
MCF7	MoTpSpVv[3Srb36gZZN{[Xl?	NVXwR\|M3OTBidV2=	NH6yeZgyOCCvaX7z		NHHJOFdU\W6\|aYTpfoF1cW:wIH;mJIlv\nKjcnXkMYlv\HWlZXSgSG5CKGSjbXHn[UBqdiCqdX3hckBOS0Z5IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBkd2yxbomg[o9zdWG2aX;uJIF1KDFyIIXNJJBz\XS{ZXH0[YQh\m:{IEGwJI1qdnNiZn;scI94\WRiYomgbZJz[WSrYYTpc44h\m:{IESgbJJ{KG2nYYP1doVlKGGodHXyJFExKGSjeYOgZpkh[3K7c4ThcEB3cW:uZYSgd5RicW6rbnegZY5idHm\|aYO=	NEfqbYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[zNlk3PSd-Mk[2N\|I6PjV:L3G+
SK-N-MC	MnHpdWhVWyCjc4PhfS=>				NX\UZ3ZzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NGX2WXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT(Ser473) / p-AKT(Thr308); PubMed: 22739265 Chin J Cancer Cells were serum-starved for 6 h and treated with KU-55933 (10 µmol/L) for 1 h before treatment with insulin (100 nmol/L) for 45 min. Cells were lysed, and cell lysates were subjected to SDS-PAGE and Western blotting for the detection of phospho-Akt at Se䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖 PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; PubMed: 22739265 Chin J Cancer ATM inhibition by KU-55933 induces apoptosis in differentiated but not undifferentiated SH-SY5Y cells. Cells were starved for 6 h in serum-free medium. KU-55933 (10 µmol/L) was added 1 h before insulin (100 nmol/L) treatment. After 3 h of insulin stimulat䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤 ATM-S1981 / ATM / p-p53(S15) / p53 ; PubMed: 20639198 J Biol Chem Antioxidant and ATM inhibitors blocked phosphorylation of ATM-S1981, Akt-S473, and p53-S15 as stimulated by H2O2 exposure. Cells were treated with 100 μm H2O2 for 30 min in the absence or presence of KU-55933. Whole cell lysates were subjected to Western 䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖 p21 / p27 / p53 ; PubMed: 20177072 J Biol Chem HMGE cells were incubated for the indicated times with 1 μm KU-55933 or DMSO. Total protein extracts were analyzed by Western blotting for p21WAF1/CIP1, p27KIP1, p53, or β-actin.	22739265 20639198 20177072
Immunofluorescence	p-S824 KAP1 / ZEBRA ; PubMed: 28249048 PLoS Pathog HH514-16 cells were treated with NaB (upper panel) or NaB plus KU-55933 (1μM; middle panel) or NaB plus Torin1 (0.5μM; lower panel) for 24 hours and stained with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification.	28249048

体内研究

KU-55933抑制ATM依赖的STAT3激活，通过上调DR5表达增强TRAIL调节的凋亡,抑制STAT3 和NF-κB都和下调cFLIP有关，伴随着凋亡水平上升。ATM抑制剂KU-55933 影响TRAIL调节的凋亡的效果比JAK2抑制剂AG490或STAT3β过量表达都高。^[3]

激酶实验： ^[1]	- 合并纯化的酶实验: 通过免疫沉淀反应从HeLa核蛋白萃取中获得用于体外研究的ATM，在反应buffer中，把兔多克隆抗血清加到ATM羧基端第400个氨基酸处，buffer包含25 mM HEPES (pH为7.4), 2 mM MgCl₂, 250 mM KCl, 500 μM EDTA, 100 μM Na₃VO₄, 10% v/v 甘油, 及0.1% v/v Igepal。和蛋白A凝胶温育1小时，然后进行离心作用，从核蛋白中分离ATM抗体复合物。在96孔板中，包含ATM的凝胶珠和1 μg 底物GST-p53N66 (p53的氮端第66位氨基酸与GST融合)在ATM实验buffer中37^oC下温育，buffer包括25 mM HEPES (pH 为7.4), 75 mM NaCl, 3 mM MgCl₂, 2 mM MnCl₂, 50 μM Na₃VO₄, 500 μM DTT, 及5% v/v甘油。震荡10分钟后，加入ATP，最终浓度为50 μM，在37^oC反应持续1小时。按250×g转速4^oC下离心10分钟，除去ATM凝胶珠，上清液转移到96孔板上，在室温下温育1.5小时。然后用PBS冲洗，烘干，加入p-p53(Ser15)抗体用于ELISA分析。使用增强的化学发光溶液产生信号和化学发光。
细胞实验： ^[1]	- 合并 Cell lines: U2OS细胞 Concentrations: 10 μM Incubation Time: 2小时 Method: U2OS细胞经过电离辐射(3, 5, 或15 Gy) 或者UV处理(5或50 J/m2)，通过p-p53（Ser15）和p53 的Western blot分析而测定ATM反应。在不同时间点获得细胞萃取物，SDS-PAGE分离蛋白，加入p-p53(Ser15)抗体，ATM增多。加入p53抗体观察到p53随着时间变化趋于稳定。为了测定KU-55933的IC50值，使用p-p53(Ser15)抗体检测KU-55933抑制ATM的效果。KU-55933加到细胞中，预温育1小时，然后进行电离辐射。在体外，使用扫描密度测定法测定IC50值。 (Only for Reference)
动物实验： ^[3]	- 合并 Animal Models: 携带LU1205细胞的BALB/c nu/nu鼠 Dosages: 10 μM Administration: -- (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	33 mg/mL (83.44 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+40%PEG300+5%Tween80+50%ddH2O	3.95 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download KU-55933 (ATM Kinase Inhibitor) SDF

分子量	395.49
化学式	C₂₁H₁₇NO₃S₂
CAS号	587871-26-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

泛ATM/ATR抑制剂

CGK 733 : Dual ATM/ATR inhibitor, IC50=~200 nM.
活性最高的ATM/ATR抑制剂

AZ20 ^New : ATR, IC50=5 nM.
用于临床的ATM/ATR抑制剂

BEZ235 (NVP-BEZ235, Dactolisib) : Phase II for Advanced Endometrial Carcinoma.
最新的ATM/ATR抑制剂

VE-822 ^New : ATR inhibitor with IC50 of 19 nM.

研究领域

产品类型

定制您的化合物库

KU-55933 (ATM Kinase Inhibitor)

客户使用Selleck生产的KU-55933 (ATM Kinase Inhibitor)发表文献237篇：

产品安全说明书

ATM/ATR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download KU-55933 (ATM Kinase Inhibitor) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

相关ATM/ATR产品